Rekha Hemrajani
Rekha Hemrajani's purchase track record
Rekha Hemrajani has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2024 | ALXO | $46K | -38.0% | -66.3% | -1.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
Transaction History
| MXCT | ▲ Buy | Grant | 30,421 | $0 | 6/17/2026 | View on chart |
| MXCT | ▼ Sell | Open Market | 10,684 | $22K | 6/25/2025 | View on chart |
| MXCT | ▲ Buy | Grant | 29,210 | $0 | 6/18/2025 | View on chart |
| ALXO | ▲ Buy | Open Market | 30,000 | $46K | 12/2/2024 | View on chart |
| MXCT | ▲ Buy | Grant | 21,367 | $0 | 6/11/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
MaxCyte Appoints New Chief Corporate Development Officer
MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.
MaxCyte Appoints New Chief Corporate Development Officer. MaxCyte has named Sidharth Kapileshwar as its new Chief Corporate Development Officer. This leadership addition focuses on corporate strategy and growth initiatives. The stock is currently trading near its 52-week low, with an average analyst target of $4.11.